2023-03-23 08:51:05 ET
- Onconova Therapeutics ( NASDAQ: ONTX ) and Pangea Biomed are collaborating to identify biomarkers of response to Onconova's cancer drug candidate rigosertib.
- The research partnership will use Pangea's proprietary algorithmic platform ENLIGHT to identify the biomarkers.
- "By leveraging Pangea’s AI platform to identify predictive biomarkers of response to rigosertib, we aim to inform a precision medicine approach to selecting additional PLK1-dependent tumors and other indications for its potential evaluation," said Onconova's President and CEO Steven Fruchtman.
- ONTX +1.11% to $0.72 premarket March 23
For further details see:
Onconova, Pangea team up to find biomarkers for cancer drug rigosertib